A Double-Blind, Placebo-Controlled, Dose Escalation Study of the Safety, Tolerability, and Pharmacokinetics of Multiple Oral Doses of KP-1461 in HIV+ Adults Who Have Failed Two or More Highly Active Antiretroviral Regimens (HAART)

Trial Profile

A Double-Blind, Placebo-Controlled, Dose Escalation Study of the Safety, Tolerability, and Pharmacokinetics of Multiple Oral Doses of KP-1461 in HIV+ Adults Who Have Failed Two or More Highly Active Antiretroviral Regimens (HAART)

Completed
Phase of Trial: Phase I

Latest Information Update: 03 Jan 2008

At a glance

  • Drugs KP 1461 (Primary)
  • Indications HIV infections
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors Koronis Pharmaceuticals
  • Most Recent Events

    • 03 Jan 2008 Status change from in progress to completed.
    • 07 Oct 2007 Interim safety results have been presented at IDSA 2007.
    • 04 Oct 2007 A total of 32 subjects have completed the study so far.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top